Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBITDA Margin (2020 - 2022)

Immuneering has reported EBITDA Margin over the past 3 years, most recently at 2886419.34% for Q4 2022.

  • Quarterly results put EBITDA Margin at 2886419.34% for Q4 2022, down 288070777.0% from a year ago — trailing twelve months through Sep 2023 was 11315518.9% (down 1130599682.0% YoY), and the annual figure for FY2022 was 15931.33%, down 1431665.0%.
  • EBITDA Margin for Q4 2022 was 2886419.34% at Immuneering, down from 33364.36% in the prior quarter.
  • Over the last five years, EBITDA Margin for IMRX hit a ceiling of 644.49% in Q3 2020 and a floor of 2886419.34% in Q4 2022.
  • Median EBITDA Margin over the past 3 years was 1771.06% (2021), compared with a mean of 268262.7%.
  • Biggest five-year swings in EBITDA Margin: plummeted -46010bps in 2021 and later crashed -288070777bps in 2022.
  • Immuneering's EBITDA Margin stood at 877.48% in 2020, then crashed by -551bps to 5711.57% in 2021, then tumbled by -50436bps to 2886419.34% in 2022.
  • The last three reported values for EBITDA Margin were 2886419.34% (Q4 2022), 33364.36% (Q3 2022), and 12223.67% (Q2 2022) per Business Quant data.